Dova Pharmaceuticals Inc (NASDAQ:DOVA) Director Steven M. Goldman purchased 5,000 shares of the business’s stock in a transaction on Thursday, June 21st. The stock was purchased at an average cost of $30.22 per share, with a total value of $151,100.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Dova Pharmaceuticals traded up $0.70, hitting $32.55, during trading hours on Monday, Marketbeat.com reports. The stock had a trading volume of 649 shares, compared to its average volume of 303,518. Dova Pharmaceuticals Inc has a one year low of $16.98 and a one year high of $37.00. The company has a market cap of $897.88 million and a price-to-earnings ratio of -22.75.
Dova Pharmaceuticals (NASDAQ:DOVA) last posted its quarterly earnings data on Wednesday, May 9th. The company reported ($0.52) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.47) by ($0.05). sell-side analysts forecast that Dova Pharmaceuticals Inc will post -2.18 earnings per share for the current fiscal year.
Several research analysts have commented on DOVA shares. BidaskClub downgraded shares of Dova Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Wednesday, May 9th. ValuEngine raised shares of Dova Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. Zacks Investment Research raised shares of Dova Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, May 14th. LADENBURG THALM/SH SH started coverage on shares of Dova Pharmaceuticals in a report on Thursday, April 26th. They issued a “buy” rating for the company. Finally, Evercore ISI started coverage on shares of Dova Pharmaceuticals in a report on Friday, March 23rd. They issued a “line” rating and a $29.00 price target for the company. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $32.00.
Several institutional investors have recently bought and sold shares of the company. Nexthera Capital LP raised its position in shares of Dova Pharmaceuticals by 25.4% during the 1st quarter. Nexthera Capital LP now owns 568,243 shares of the company’s stock valued at $15,411,000 after buying an additional 115,211 shares in the last quarter. Jane Street Group LLC purchased a new stake in shares of Dova Pharmaceuticals during the 1st quarter valued at $220,000. venBio Select Advisor LLC purchased a new stake in shares of Dova Pharmaceuticals during the 1st quarter valued at $3,390,000. Pier Capital LLC raised its position in shares of Dova Pharmaceuticals by 36.1% during the 1st quarter. Pier Capital LLC now owns 217,885 shares of the company’s stock valued at $5,909,000 after buying an additional 57,762 shares in the last quarter. Finally, Citigroup Inc. raised its position in shares of Dova Pharmaceuticals by 4,519.6% during the 1st quarter. Citigroup Inc. now owns 65,968 shares of the company’s stock valued at $1,789,000 after buying an additional 64,540 shares in the last quarter. Hedge funds and other institutional investors own 35.93% of the company’s stock.
About Dova Pharmaceuticals
Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead drug candidate is avatrombopag that has completed Phase III clinical trials for the treatment of thrombocytopenia in patients with chronic liver disease.
Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.